Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Pancreatic Neoplasms 685Cholangiocarcinoma 113Biliary Tract Neoplasms 95Neoplasms 69Neoplasm Metastasis 66Gallbladder Neoplasms 61Colorectal Neoplasms 49Bile Duct Neoplasms 40Carcinoma, Non-Small-Cell Lung 37Adenocarcinoma 28Carcinoma, Hepatocellular 26Stomach Neoplasms 22Liver Neoplasms 21Colonic Neoplasms 21Ovarian Neoplasms 20Lung Neoplasms 19Breast Neoplasms 18Rectal Neoplasms 15Carcinoma, Pancreatic Ductal 15Pancreatic Adenocarcinoma 13Esophageal Neoplasms 13Sarcoma 12Carcinoma 11Small Cell Lung Carcinoma 10Urinary Bladder Neoplasms 9Gastrointestinal Neoplasms 9Advanced Pancreatic Cancer 9Triple Negative Breast Neoplasms 8Squamous Cell Carcinoma of Head and Neck 8Recurrence 8

Interventions

Gemcitabine 2selicrelumab 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Adenocarcinoma Pancreas × Gemcitabine × Gastrointestinal × Clear all
NCT02812992 2021-08-10

GrantPax

AIO-Studien-gGmbH

Phase 4 Completed
32 enrolled
Gastrointestinal

Adenocarcinoma Pancreas

NCT01456585 2018-08-27

Phase 1 Study of Preoperative Gemcitabine Plus CP-870, 893 Followed by Addition of CP-870,893 to Standard -Of-care Adjuvant Chemoradiation for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma

Abramson Cancer Center at Penn Medicine

Phase 1 Completed
10 enrolled
Gastrointestinal

Adenocarcinoma Pancreas

Data powered by HemOnc (CC BY 4.0) Colophon âš¡